Weekly Recap | LIVZON PHARMA +1.46%, outperforming the Hang Seng IndexWeekly Review·Nov 14, 2026 at 05:08 AM01513-1.28%
Livzon Pharmaceutical Files List of Board and Committee MembersPUBT·Nov 12, 2026 at 12:34 PM01513-1.28%000513-2.22%
Livzon Pharmaceutical to Buy 0.13% Stake in Xinbeijiang Pharma for RMB 3.85 MillionPUBT·Nov 11, 2026 at 12:29 PM01513-1.28%000513-2.22%
Livzon Pharma climbs 5% on Wandai Tang Granules approvalMarket Movers·Oct 30, 2026 at 06:04 AM01513-1.28%
Livzon Subsidiary MABPharm Wins China Approval for Phase I Trial of Anti-FXI AntibodyPUBT·Oct 27, 2026 at 08:49 AM01513-1.28%
Livzon Pharmaceutical surges 10% on Q3 dividend planHK Stock Market Update·Oct 26, 2026 at 01:34 AM01513-1.28%
Pharma Giants Pivot to Cash Flow: $1.99B Exit and 90% Dividend RuleGlobal Report·Oct 23, 2026 at 09:14 AM02607+0.09%01513-1.28%
Livzon Pharmaceutical Proposes Third-Quarter Dividend of RMB 12.39 per 10 SharesPUBT·Oct 23, 2026 at 08:49 AM01513-1.28%000513-2.22%
Livzon Pharmaceutical Sees Profit and Revenue Drop in Q3 2026Tip Ranks·Oct 23, 2026 at 08:39 AM01513-1.28%
Livzon Pharmaceutical Group Unveils Three-Year Shareholder Return PlanTip Ranks·Oct 23, 2026 at 08:39 AM01513-1.28%000513-2.22%
Weekly Recap | LIVZON PHARMA -4.41%, consensus target above spotWeekly Review·Oct 17, 2026 at 05:25 AM01513-1.28%
Livzon Pharmaceutical Schedules Board Meeting to Review Q3 Results and Potential DividendTip Ranks·Oct 12, 2026 at 09:11 AM01513-1.28%000513-2.22%